Immunopharmacology of 5-(3,3-dIMETHYL-1-triazeno)-imidazole-4-carboxamide (DTIC) (DTIC)
- 31 December 1975
- journal article
- review article
- Published by Elsevier in Pharmacological Research Communications
- Vol. 7 (6) , 481-491
- https://doi.org/10.1016/0031-6989(75)90009-0
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Brief Communication: Increased Immunogenicity of Two Lymphoma Lines After Drug Treatment of Athymic (Nude) MiceJNCI Journal of the National Cancer Institute, 1975
- Cellular immune response to a drug-treated L5178Y lymphoma sublineNature, 1974
- Brief Communication: Antigenic Changes Associated With Resistance to Methotrexate and 6-Mercaptopurine in L1210 Ascites Lymphoma 2JNCI Journal of the National Cancer Institute, 1974
- Heterotransplantation of Human Malignant Tumors in “Nude” Thymusless Mice. II. Malignant Tumors Induced by Injection of Cell Cultures Derived From Human Solid Tumors 2JNCI Journal of the National Cancer Institute, 1974
- Triple combination chemotherapy of disseminated melanomaCancer, 1972
- Imidazole carboxamide therapy in advanced malignant melanomaCancer, 1971
- Demonstration of cell‐mediated immunity to human neoplasms of various histological typesInternational Journal of Cancer, 1971
- Clinical Evaluation of 5-(3,3-Dimethyl-1-Triazeno) Imidazole-4-Carboxamide in Malignant Melanoma and Other Neoplasms: Comparison of Twice-weekly and Daily Administration SchedulesOncology, 1971
- Some Pharmacokinetic Aspects of 5-(Dimethyltriazeno)-imidazole-4-carboxamide in the DogJournal of Pharmaceutical Sciences, 1968
- Tumor AntigensAnnual Review of Microbiology, 1966